0001567619-18-001205.txt : 20180815 0001567619-18-001205.hdr.sgml : 20180815 20180815172324 ACCESSION NUMBER: 0001567619-18-001205 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180813 FILED AS OF DATE: 20180815 DATE AS OF CHANGE: 20180815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bilenker Joshua H. CENTRAL INDEX KEY: 0001612312 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181021792 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-08-13 0 0001581720 Loxo Oncology, Inc. LOXO 0001612312 Bilenker Joshua H. C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 1 1 0 0 President & CEO Common Stock 2018-08-13 4 M 0 10000 1.184 A 145407 D Common Stock 2018-08-13 4 S 0 1600 157.6677 D 143807 D Common Stock 2018-08-13 4 S 0 4233 158.5098 D 139574 D Common Stock 2018-08-13 4 S 0 3367 159.6267 D 136207 D Common Stock 2018-08-13 4 S 0 800 160.4862 D 135407 D Common Stock 2018-08-14 4 M 0 10000 1.184 A 145407 D Common Stock 2018-08-14 4 S 0 1600 159.1263 D 143807 D Common Stock 2018-08-14 4 S 0 7100 159.9311 D 136707 D Common Stock 2018-08-14 4 S 0 1300 160.7508 D 135407 D Common Stock 30000 I By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 Employee Stock Option (Right to Buy) 1.184 2018-08-13 4 M 0 10000 0 D 2023-11-14 Common Stock 10000 83932 D Employee Stock Option (Right to Buy) 1.184 2018-08-14 4 M 0 10000 0 D 2023-11-14 Common Stock 10000 73932 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.99 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.13 to $160.07 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.17 to $160.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.41 to $159.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.47 to $160.46 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.47 to $161.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The options have fully vested and are immediately exercisable. /s/Jennifer Burstein, by power of attorney 2018-08-14